The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review
Immunotherapy has emerged as a pivotal component in the treatment of various malignancies, encompassing lung, skin, gastrointestinal, and head and neck cancers. The foundation of this therapeutic approach lies in immune checkpoint inhibitors (ICI). While ICIs have demonstrated remarkable efficacy in...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/3/611 |
| _version_ | 1797318918817185792 |
|---|---|
| author | Antonietta Gerarda Gravina Raffaele Pellegrino Alfonso Esposito Marina Cipullo Mario Romeo Giovanna Palladino Patrizia Iodice Alessandro Federico Teresa Troiani |
| author_facet | Antonietta Gerarda Gravina Raffaele Pellegrino Alfonso Esposito Marina Cipullo Mario Romeo Giovanna Palladino Patrizia Iodice Alessandro Federico Teresa Troiani |
| author_sort | Antonietta Gerarda Gravina |
| collection | DOAJ |
| description | Immunotherapy has emerged as a pivotal component in the treatment of various malignancies, encompassing lung, skin, gastrointestinal, and head and neck cancers. The foundation of this therapeutic approach lies in immune checkpoint inhibitors (ICI). While ICIs have demonstrated remarkable efficacy in impeding the neoplastic progression of these tumours, their use may give rise to substantial toxicity, notably in the gastrointestinal domain, where ICI colitis constitutes a significant aspect. The optimal positioning of Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway inhibitors in the therapeutic management of ICI colitis remains unclear. Numerous reports have highlighted notable improvements in ICI colitis through the application of pan-JAK-STAT inhibitors, with tofacitinib, in particular, reporting evident clinical remission of colitis. The precise mechanism by which JAK-STAT inhibitors may impact the pathogenetic process of ICI colitis remains inadequately understood. However, there is speculation regarding their potential role in modulating memory resident CD8<sup>+</sup> T lymphocytes. The elucidation of this mechanism requires further extensive and robust evidence, and ongoing JAK-STAT-based trials are anticipated to contribute valuable insights. |
| first_indexed | 2024-03-08T03:59:24Z |
| format | Article |
| id | doaj.art-3b59b351e00b44c9b33f0e066b9cad76 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-08T03:59:24Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-3b59b351e00b44c9b33f0e066b9cad762024-02-09T15:09:21ZengMDPI AGCancers2072-66942024-01-0116361110.3390/cancers16030611The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative ReviewAntonietta Gerarda Gravina0Raffaele Pellegrino1Alfonso Esposito2Marina Cipullo3Mario Romeo4Giovanna Palladino5Patrizia Iodice6Alessandro Federico7Teresa Troiani8Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, ItalyHepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, ItalyOncology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, ItalyHepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, ItalyHepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, ItalyHepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, ItalyOncology Division, AORN Ospedali Dei Colli, Monaldi Hospital, Via L. Bianchi, 80131 Naples, ItalyHepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, ItalyOncology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, ItalyImmunotherapy has emerged as a pivotal component in the treatment of various malignancies, encompassing lung, skin, gastrointestinal, and head and neck cancers. The foundation of this therapeutic approach lies in immune checkpoint inhibitors (ICI). While ICIs have demonstrated remarkable efficacy in impeding the neoplastic progression of these tumours, their use may give rise to substantial toxicity, notably in the gastrointestinal domain, where ICI colitis constitutes a significant aspect. The optimal positioning of Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway inhibitors in the therapeutic management of ICI colitis remains unclear. Numerous reports have highlighted notable improvements in ICI colitis through the application of pan-JAK-STAT inhibitors, with tofacitinib, in particular, reporting evident clinical remission of colitis. The precise mechanism by which JAK-STAT inhibitors may impact the pathogenetic process of ICI colitis remains inadequately understood. However, there is speculation regarding their potential role in modulating memory resident CD8<sup>+</sup> T lymphocytes. The elucidation of this mechanism requires further extensive and robust evidence, and ongoing JAK-STAT-based trials are anticipated to contribute valuable insights.https://www.mdpi.com/2072-6694/16/3/611immunotherapyimmune checkpoint inhibitorscolitisJAK-STATtofacitinibimmune-related adverse events |
| spellingShingle | Antonietta Gerarda Gravina Raffaele Pellegrino Alfonso Esposito Marina Cipullo Mario Romeo Giovanna Palladino Patrizia Iodice Alessandro Federico Teresa Troiani The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review Cancers immunotherapy immune checkpoint inhibitors colitis JAK-STAT tofacitinib immune-related adverse events |
| title | The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review |
| title_full | The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review |
| title_fullStr | The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review |
| title_full_unstemmed | The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review |
| title_short | The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review |
| title_sort | jak stat pathway as a therapeutic strategy in cancer patients with immune checkpoint inhibitor induced colitis a narrative review |
| topic | immunotherapy immune checkpoint inhibitors colitis JAK-STAT tofacitinib immune-related adverse events |
| url | https://www.mdpi.com/2072-6694/16/3/611 |
| work_keys_str_mv | AT antoniettagerardagravina thejakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT raffaelepellegrino thejakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT alfonsoesposito thejakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT marinacipullo thejakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT marioromeo thejakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT giovannapalladino thejakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT patriziaiodice thejakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT alessandrofederico thejakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT teresatroiani thejakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT antoniettagerardagravina jakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT raffaelepellegrino jakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT alfonsoesposito jakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT marinacipullo jakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT marioromeo jakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT giovannapalladino jakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT patriziaiodice jakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT alessandrofederico jakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview AT teresatroiani jakstatpathwayasatherapeuticstrategyincancerpatientswithimmunecheckpointinhibitorinducedcolitisanarrativereview |